PTC725
/ PTC Therapeutics
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
September 14, 2016
PTC725, an NS4B-targeting compound, inhibits an HCV genotype 3 replicon, as predicted by genome sequence analysis and determined experimentally.
(PubMed)
- "This is the first report of the activity of an NS4B targeting compound against HCV gt3. Additionally, we have identified previously unreported amino acid substitutions selected by PTC725 treatment which further demonstrate that these compounds target the NS4B first transmembrane region."
Journal • Biosimilar • Hepatitis C Virus • Immunology • Infectious Disease
1 to 1
Of
1
Go to page
1